PharmaCyte Biotech Inc (PMCB)

[mick]

his one could be your best shot my friend/

re;
$PMCB Follow The Bread Crumbs to the FDA for PharmaCyte (PMCB)



It seems the market is ready to hear PMCB is finally going to file its long awaited NDA- NDA is the acronym for "New Drug Application".

This is the blue print that is submitted to the FDA in order to start the approval process for a new drug.

For the last couple of years PMCB has been performing numerous
studies to prepare for this filing
- the first to be a therapy for Pancreatic Cancer.

My suspicion is PMCB will finally file its NDA sometime before the
end of 2015,
and when it does so the stock is likely to explode up the charts
and demonstrate this technology has every opportunity for commercial success.

Fortunes are made by investors who can
"follow the bread crumbs"
- the little, innocuous clues that appear which eventually lead to success.

Not everyone will get the significance of Dr. Hidalgo's addition to the advisory board, but I'm here to help.

Dr. Daniel Von Hoff is the first crumb to follow.
Von Hoff's cancer research firm is doing studies for PMCB.

For 6 years,
Von Hoff served as the head of President Bush's national cancer advisory board.

He is the past president of the American Association for Cancer Research- the largest cancer research organization in the world.

If you check his bio online,
you will learn Von Hoff was intimately involved with the early studies on Gemcitabine-
also known as Gemzar
- the gold standard treatment for Pancreatic Cancer.

As it turns out,
Dr. Manuel Hidlalgo was an assistant Professor of Medicine under
Dr. Von Hoff at The University of Texas.
Von Hoff and Hidalgo have served on many advisory boards together
for cancer therapy drugs that ended up going to market.

Von Hoff and Hidlalgo also cofounded the Pancreatic Cancer Research
Team that was instrumental in bringing Abraxane to market.

http://finance.yahoo.com/news/pharmacyte-biotech-present-cancer-diabetes-132000294.html

So, if you're following the bread crumbs,
they inevitably lead to a team of the world's foremost experts on Pancreatic Cancer being assembled to move this technology towards getting into the FDA Approval process.

They are bringing in a deep bench for the pennant run.

As far as the stock goes,
kind of a typical,
lack luster summer doldrums pattern.
It's down to its support level on low volume.

If you're a multi month investor,
and can recall all the surges this stock has made over the
3 plus years I've covered it,
you already know this is a great time to accumulate.

One pretty good run happened back in April, so we could be closing
in on the next surge.

It's easy to predict it will happen, it's just hard to predict exactly when.